Initial Intrathecal Dose Titration and Predictors of Early Dose Escalation in Patients With Cancer Using a 100:1 Oral to Intrathecal Morphine Conversion Ratio.

Jill E Sindt Daniel W OdellRayhan TariqAngela P PressonChong ZhangShane E Brogan

Published in: Neuromodulation : journal of the International Neuromodulation Society (2021)

An oral-to-intrathecal morphine conversion ratio of approximately 100:1 for initiation of IDD in patients with cancer pain was safe and well tolerated and may facilitate rapid elimination of systemic opioids. Dose reduction was rare, while a majority of patients required further dose escalation prior to discharge.

Keyphrases

chronic pain
end stage renal disease
newly diagnosed
pain management
open label
prognostic factors
neuropathic pain
patient reported outcomes
patient reported